Sat, Dec 20, 2014, 5:25 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Sucampo Pharmaceuticals, Inc. (SCMP) Message Board

  • biotuesday biotuesday Sep 4, 2013 12:37 PM Flag

    BioTuesdays: Cantor says Sucampo weakness overdone

    Cantor Fitzgerald analyst Irina Rivkind says shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) are trading off on a recent downgrade of competitor Ironwood Pharmaceuticals (NASDAQ:IRWD), reflecting news that Ironwood’s Linzess will be priced below Sucampo’s Amitiza.

    A Cowen & Co. analyst downgraded shares of Ironwood on Monday, citing the company’s growing expenses and disappointing early sales of its bowel drug Linzess.

    Ms. Rivkind writes that the Linzess pricing strategy was the subject of a recent BioCentury article that highlighted Ironwood’s attempts to gain improved reimbursement for Linzess by entering the market at a lower price than Amitiza on launch last December.

    “We note that there is nothing new in this BioCentury article........

    See BioTuesdays for rest of brief.

13.57+0.13(+0.97%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.